Please assess the completion status of the following clinical trial:

Trial Title: Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion~* Patients must have histologically confirmed liposarcoma, which is recurrent, metastatic or unresectable~* There is no limit to prior chemotherapy regimens; in addition, patients may have prior radiation~* All patients must have measurable disease, defined as lesions that can be accurately measured in at least one dimension (\>= 20 mm with conventional techniques or \>= 10mm with spiral CT scan); pleural effusions and ascites will not be considered measurable, but may be present in addition to the measurable lesion(s)~* ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2; patients should have an expected survival of at least 3 months~* Absolute neutrophil count \>= 1,000/ul~* Platelets \>= 75000/ul~* Total bilirubin =\< 2.0 g/dl~* AST(SGOT)/ALT(SGPT) =\< 2.0X institutional upper limit of normal~* Brain metastasis is not an exclusion; however, patients are only eligible if they have had successful control of the brain tumor(s) by surgery or radiation therapy~* All prior therapy must have been completed at least 3 weeks prior to the patient's entry on this trial~* No concurrent chemotherapy, radiotherapy, immunotherapy or other investigational agents~* Women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; should a women become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately~* Ability to understand and willingness to sign a written informed consent document~Exclusion~* Patient has had prior treatment with or is currently taking a protease inhibitor~* Patients enrolled cannot be on the following medications: cisapride, triazolam, midazolam, ergot derivatives, amiodarone, quinidine, dihydropyridine calcium antagonists (amlodipine, felodipine, isradipine, nicardipine, nifedipine, nimodipine, and nisoldipine), sildenafil, dilantin, rifampin or oral contraceptives~* Uncontrolled intercurrent illness~* Patients must have recovered from any expected toxicities of previous chemotherapy or radiation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).